View Author
t cells receptor expression patient lymphocytes cancer cytokine transduction production level t lymphocytes psoriatic response therapy fibroblast tumor culture t-cell antigen immunol activation transfer epidermal activity antibody target il -15 interleukin number psoriasis study keratinocyte protein chain transduced medium result chapter assay control vector clone pp ec blood binding figure treatment speci melanoma surface factor domain rtvsup sample peptide molecule -15 il -21 transgene il -6 jurkat t cells epidermis table virus -21 lesional serum function donor lamer protocol growth jurkat dermatol chimeric nn fibroblasts il -2 tcr gene transfer release surface expression
10 Most Recent Publications
|
Long-term stability of T-cell activation and transduction components critical to the processing of clinical batches of gene-engineered T cells
(Article)
Lamers, C.H.J. Elzakker, P.M.M.L. van Steenbergen, S.L.C. van Luider, B.A. Groot, C. Krimpen, B.A. van Vulto, A.G. Sleijfer, S. Debets, J.E.M.A. Gratama, J-W. |
2013-05-01
|
|
T cell receptor fused to CD3ζ: Transmembrane domain of CD3ζ prevents TCR mis-pairing, whereas complete CD3ζ directs functional TCR expression
(Article)
Govers, C. Sebestyén, Z. Berrevoets, C.A. Venselaar, H. Debets, J.E.M.A. |
2011-10-11
|
|
T-cell synapse formation depends on antigen recognition but not CD3 interaction: Studies with TCR:ζ, a candidate transgene for TCR gene therapy
(Article)
Roszik, J. Sebestyén, Z. Govers, C. Guri, Y. Szöor, Á. Pályi-Krekk, Z. Vereb, G. Nagy, P. Szöllosi, J. Debets, J.E.M.A. |
2011-05-01
|
|
Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells
(Article)
Lamers, C.H.J. Willemsen, R.A. Elzakker, P.M.M.L. van Steenbergen-Langeveld, S. van Broertjes, M. Oosterwijk-Wakka, J. Oosterwijk, E. Sleijfer, S. Debets, J.E.M.A. Gratama, J-W. |
2011-01-06
|
|
mRNA levels of CD31, CD144, CD146 and von Willebrand factor do not serve as surrogate markers for circulating endothelial cells
(Article)
Strijbos, M.H. Krimpen, B.A. van Debets, J.E.M.A. Kraan, J. Sleijfer, S. Gratama, J-W. Lamers, C.H.J. |
2010-08-01
|
|
T cell activation upon exposure to patient-derived tumor tissue: A functional assay to select patients for adoptive T cell therapy
(Article)
Schroten-Loef, C. Kraaij, R. Veldhoven, J.L.M. Berrevoets, C.A. Bakker, M.A. den Sadelain, M. Bangma, C.H. Willemsen, R.A. Debets, J.E.M.A. |
2010-07-01
|
|
Combination of IL-21 and IL-15 enhances tumour-specific cytotoxicity and cytokine production of TCR-transduced primary T cells
(Article)
Pouw, N.M.C. Treffers-Westerlaken, E. Kraan, J. Wittink, F. Hagen, T.L.M. ten Verweij, J. Debets, J.E.M.A. |
2010-06-01
|
|
Development of adoptive cell therapy for cancer: A clinical perspective
(Article)
Hawkins, R.E. Gilham, D.E. Debets, J.E.M.A. Eshhar, Z. Taylor, N. Abken, H. Schumacher, T.N. |
2010-06-01
|
|
MHC class I molecules with superenhanced CD8 binding properties bypass the requirement for cognate TCR recognition and nonspecifically activate CTLs
(Article)
Wooldridge, L. Clement, M. Debets, J.E.M.A. Berrevoets, C.A. Miles, J.J. Burrows, S.R. Price, D.A. Sewell, A.K. Lissina, A. Edwards, E.S.J. Ladell, K. Ekeruche, J. Hewitt, R.E. Laugel, B. Gostick, E. Cole, D.K. |
2010-04-01
|
|
T cell receptor (TCR) gene therapy to treat melanoma: Lessons from clinical and preclinical studies
(Article)
Coccoris, M. Straetemans, G.C.M. Govers, C. Lamers, C.H.J. Sleijfer, S. Debets, J.E.M.A. |
2010-04-01
|
